


Vascular targeted photodynamic tx aids low-risk prostate cancer

25 July 2017



percent rate of absent clinically significant cancer in treated lobes and 76 percent of [patients](#) avoided radical therapy at a median follow-up of 68 months," the authors write. "However, longer term follow-up is required to determine long-term outcomes."

One author disclosed financial ties to Steba Biotech, which funded the study.

More information: [Abstract](#)
[Full Text](#)

Copyright © 2017 [HealthDay](#). All rights reserved.

(HealthDay)—For men with low-risk prostate cancer, vascular targeted photodynamic therapy achieves an 82 percent rate of absent clinically significant cancer in treated lobes, according to a study published in the August issue of *The Journal of Urology*.

Souhil Lebdaï, M.D., from the University Hospital of Angers in France, and colleagues followed 82 men treated with vascular targeted photodynamic therapy for [low-risk prostate cancer](#) every six months. Six months after treatment or when there was biological or clinical progression, patients underwent [prostate biopsies](#).

Patients were followed for a median of 68 months. The researchers found that median progression-free survival was 86 months. Six months after treatment, there was a significant 41 percent decrease in median prostate-specific antigen, which remained stable during follow-up (P

"Padeliporfin vascular targeted [photodynamic therapy](#) for low-risk prostate cancer achieved an 82

APA citation: Vascular targeted photodynamic tx aids low-risk prostate cancer (2017, July 25) retrieved 18 June 2019 from <https://medicalxpress.com/news/2017-07-vascular-photodynamic-tx-aids-low-risk.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.